 Caitlin Lewis
Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Superoxide Dismutase | 2 | 2025 | 322 | 1.630 |
Why?
| | Hypoxia | 3 | 2025 | 1031 | 1.300 |
Why?
| | Macrophages | 5 | 2025 | 1463 | 1.150 |
Why?
| | Hyaluronic Acid | 1 | 2025 | 212 | 0.830 |
Why?
| | Drinking Water | 1 | 2022 | 76 | 0.710 |
Why?
| | Intestinal Absorption | 1 | 2020 | 96 | 0.680 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 60 | 0.680 |
Why?
| | Interleukin-4 | 2 | 2023 | 213 | 0.670 |
Why?
| | Hypertension, Pulmonary | 3 | 2025 | 1735 | 0.660 |
Why?
| | Cardiovascular Agents | 1 | 2020 | 151 | 0.620 |
Why?
| | Cardiovascular System | 1 | 2020 | 139 | 0.620 |
Why?
| | Anemia, Sickle Cell | 1 | 2022 | 252 | 0.600 |
Why?
| | Intestines | 1 | 2020 | 345 | 0.560 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2065 | 0.540 |
Why?
| | Interferon-gamma | 1 | 2019 | 761 | 0.520 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 856 | 0.510 |
Why?
| | Fibroblasts | 2 | 2025 | 939 | 0.500 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 635 | 0.410 |
Why?
| | Cardiovascular Diseases | 2 | 2023 | 2018 | 0.390 |
Why?
| | Extracellular Matrix | 2 | 2025 | 497 | 0.350 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 5257 | 0.280 |
Why?
| | Mice | 7 | 2025 | 16579 | 0.270 |
Why?
| | Superoxides | 3 | 2025 | 196 | 0.270 |
Why?
| | Signal Transduction | 1 | 2019 | 4829 | 0.260 |
Why?
| | Reactive Oxygen Species | 2 | 2025 | 579 | 0.240 |
Why?
| | Mice, Knockout | 4 | 2025 | 2752 | 0.240 |
Why?
| | Animals | 8 | 2025 | 34501 | 0.230 |
Why?
| | Inflammation | 2 | 2025 | 2664 | 0.230 |
Why?
| | Cellular Reprogramming | 1 | 2024 | 95 | 0.220 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 174 | 0.220 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2025 | 245 | 0.210 |
Why?
| | Vascular Remodeling | 1 | 2025 | 181 | 0.210 |
Why?
| | beta-Thalassemia | 1 | 2023 | 36 | 0.210 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 55 | 0.210 |
Why?
| | Interleukin-13 | 1 | 2023 | 145 | 0.200 |
Why?
| | Wound Healing | 1 | 2025 | 310 | 0.200 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2025 | 417 | 0.200 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2022 | 46 | 0.200 |
Why?
| | Aortic Diseases | 1 | 2023 | 113 | 0.190 |
Why?
| | Biological Availability | 1 | 2022 | 123 | 0.190 |
Why?
| | Oxidative Stress | 2 | 2025 | 1188 | 0.190 |
Why?
| | Hindlimb | 1 | 2022 | 125 | 0.190 |
Why?
| | Macrophages, Alveolar | 1 | 2024 | 379 | 0.180 |
Why?
| | Necrosis | 1 | 2022 | 231 | 0.180 |
Why?
| | Neovascularization, Physiologic | 1 | 2022 | 172 | 0.180 |
Why?
| | Arginine | 1 | 2022 | 258 | 0.170 |
Why?
| | Permeability | 1 | 2020 | 156 | 0.170 |
Why?
| | Chemokine CXCL11 | 1 | 2019 | 3 | 0.170 |
Why?
| | Chemokine CCL22 | 1 | 2019 | 3 | 0.170 |
Why?
| | Receptors, CCR7 | 1 | 2019 | 27 | 0.170 |
Why?
| | Regional Blood Flow | 1 | 2022 | 462 | 0.170 |
Why?
| | THP-1 Cells | 1 | 2019 | 24 | 0.170 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 38 | 0.170 |
Why?
| | Chemokines, CC | 1 | 2019 | 32 | 0.170 |
Why?
| | Catalase | 1 | 2019 | 122 | 0.160 |
Why?
| | Atherosclerosis | 1 | 2023 | 405 | 0.160 |
Why?
| | Collagen Type I | 1 | 2019 | 118 | 0.160 |
Why?
| | Primary Cell Culture | 1 | 2019 | 159 | 0.160 |
Why?
| | Coculture Techniques | 1 | 2019 | 225 | 0.160 |
Why?
| | Ischemia | 1 | 2022 | 395 | 0.150 |
Why?
| | Macrophage Activation | 1 | 2019 | 186 | 0.150 |
Why?
| | Receptors, Immunologic | 1 | 2019 | 209 | 0.150 |
Why?
| | Hydrogen Peroxide | 1 | 2019 | 308 | 0.150 |
Why?
| | Interleukin-1beta | 1 | 2019 | 374 | 0.140 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 571 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 466 | 0.140 |
Why?
| | Nitric Oxide | 1 | 2022 | 886 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1001 | 0.130 |
Why?
| | Angiotensin II | 1 | 2015 | 93 | 0.120 |
Why?
| | Lung | 2 | 2025 | 3741 | 0.120 |
Why?
| | Polyethylene Glycols | 1 | 2019 | 597 | 0.120 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1639 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2506 | 0.090 |
Why?
| | Vascular Stiffness | 1 | 2015 | 476 | 0.080 |
Why?
| | B-Lymphocytes | 1 | 2015 | 820 | 0.080 |
Why?
| | Male | 3 | 2025 | 62883 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2025 | 3943 | 0.070 |
Why?
| | Humans | 5 | 2024 | 128524 | 0.070 |
Why?
| | Hypertension | 1 | 2015 | 1238 | 0.070 |
Why?
| | Platelet Factor 4 | 1 | 2025 | 32 | 0.060 |
Why?
| | Platelet Activation | 1 | 2025 | 82 | 0.060 |
Why?
| | Phenylhydrazines | 1 | 2023 | 3 | 0.060 |
Why?
| | Iron Chelating Agents | 1 | 2023 | 17 | 0.050 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 68 | 0.050 |
Why?
| | Hemopexin | 1 | 2023 | 27 | 0.050 |
Why?
| | Heme | 1 | 2023 | 76 | 0.050 |
Why?
| | Hemolysis | 1 | 2023 | 199 | 0.050 |
Why?
| | Blood Platelets | 1 | 2025 | 369 | 0.050 |
Why?
| | B-Cell Activation Factor Receptor | 1 | 2015 | 13 | 0.030 |
Why?
| | Antigens, CD20 | 1 | 2015 | 27 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 1985 | 0.030 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2015 | 57 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2015 | 216 | 0.030 |
Why?
| | Spleen | 1 | 2015 | 513 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 448 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2015 | 837 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2335 | 0.020 |
Why?
| | Female | 2 | 2025 | 68127 | 0.020 |
Why?
| | Child | 1 | 2023 | 20721 | 0.010 |
Why?
|
|
Lewis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|